Breaking Finance News

Zacks Investment Research announced Novo Nordisk A S (ADR) (NYSE:NVO), bumping up its price target to $49.00 earlier today

Indicating a possible upside of 0.13%, Zacks Investment Research raised the target of Novo Nordisk A S (ADR) (NYSE:NVO) to $49.00

Boasting a price of $43.54, Novo Nordisk A S (ADR) (NYSE:NVO) traded -0.95% lower on the day. With the last stock price close up 17.97% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. Novo Nordisk A S (ADR) has recorded a 50-day average of $45.61 and a two hundred day average of $40.85. Volume of trade was up over the average, with 2,037,890 shares of NVO changing hands over the typical 1,713,110

Performance Chart

Novo Nordisk A S (ADR) (NYSE:NVO)

With a total market value of $0, Novo Nordisk A S (ADR) has 52 week low of $30.89 and a 52 week high of $48.88 with a P/E ratio of 19.47 .

General Information About Novo Nordisk A S (ADR) (NYSE:NVO)

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *